Tag: cytotoxic payload

Antibody–drug conjugates (ADCs) are a rapidly evolving class of targeted chemotherapeutics that combine the tumor selectivity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule payloads. Through rational linker design and optimized bioconjugation, ADCs have steadily advanced toward the goal of precision cancer therapy, achieving enhanced efficacy and reduced off-target toxicity. As of 2026, more than 15 ADCs have been approved globally for hematologic and solid tumors, with over 2,000 candidates in development and worldwide sales projected to exceed $16 billion

Authors: Donaghy H. Title: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates Published in: MAbs. 2016 May-Jun;8(4):659-71. doi: 10.1080/19420862.2016.1156829....